First-in-Human, Multicenter, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of YL-18319 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
First-in-Human, multicenter, phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of YL-18319 monotherapy treatment in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies.
Epistemonikos ID: 14be595cfd2e3d7920438095092b497a77ef15ff
First added on: Oct 30, 2026